Related Experiment Video
Updated: Aug 7, 2026
12:36
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
Proteomic biomarkers for autoimmune disease
Wolfgang Hueber1, William H Robinson
1Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, CA, USA. whueber@stanford.edu
Proteomics
|June 21, 2006
Summary
Proteomics technologies offer new ways to find unique biomarkers for diagnosing and treating autoimmune diseases, improving patient care. These advanced methods enhance our understanding of these complex conditions.
Area of Science:
- Immunology and Molecular Biology
- Biomedical Diagnostics
Background:
- Autoimmune diseases impact 3% of the global population.
- Current diagnostic methods rely on clinical examination, laboratory tests, and imaging.
- There is a need for more precise diagnostic and classification tools.
Purpose of the Study:
- To review recent advancements in proteomics technologies.
- To explore the application of proteomics in diagnosing and classifying autoimmune diseases.
- To highlight the potential of proteomics in guiding therapeutic decisions.
Main Methods:
- Review of current scientific literature on proteomics technologies.
- Analysis of studies applying proteomics to autoimmune disease research.
- Synthesis of findings on novel biosignatures identified through proteomics.
Main Results:
- Proteomics enables the identification of novel biosignatures for autoimmune diseases.
- These biosignatures can improve diagnostic accuracy and disease classification.
- Proteomic data can inform personalized treatment strategies.
Conclusions:
- Proteomics technologies represent a significant advancement in autoimmune disease research.
- The application of proteomics holds promise for transforming the diagnosis and management of autoimmune conditions.
- Further research is needed to fully integrate proteomics into clinical practice.
